Autopsy report · NCT00183989

Combination Therapy With Fludarabine, Mitoxantrone and Rituximab in Mantle Cell Lymphoma

“Insufficient accrual”

The sponsor’s own words in the registry.

Life of this trial

• Registered 5 years 1 month after it had already started.
• Ran for about 6 years 4 months before it stopped.
• 30 participants planned (an estimate, not an actual count).
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

University of Southern California

Sponsor type

University, hospital or other

Conditions

Mantle Cell Lymphoma

Interventions

Fludarabine, Mitoxantrone and Rituximab

Participants

30 (planned, not actual)

Sites

1

Countries

United States

Trials that died the same way

• TACE Plus Axitinib and Hydroxychlorquine for Liver-Dominant Metastatic Colorectal Cancer (CRC)
  “failure to accrue” (89% match in meaning)
• Phase 2 Study to Determine if RTB101 Reduces the Severity of COVID-19 in Older Adults Residing in Nursing Homes
  “Insufficient accrual rate” (85% match in meaning)
• Effect of Metformin on Biomarkers of Colorectal Tumor Cell Growth
  “Inadequate accrual” (84% match in meaning)
• Osteoarthritis Shoulder Injection Study
  “insufficient rate of accrual” (83% match in meaning)
• A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms
  “unable to accrue” (83% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.